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SummAry – First cancer vaccine that was approved for routine therapy was sipuleucel-t for 
treatment of patients with metastatic castration resistant prostate cancer. however, other immuno-
therapy drugs evaluated in prostate cancer, particularly immune checkpoint inhibitors, have failed to 
show therapeutic effect. There are several potential explanations for lack of response of prostate cancer 
to these drugs. These explanations, which are related to specific genetic (e.g. low mutational burden) 
and immunological (e.g. immunosuppressive tumor immune microenvironment) background of pros-
tate cancer are discussed in this review. Also, new therapeutic strategies to overcome prostate cancer 
immunotherapy resistance and to select subgroups of patients that could benefit from immunotherapy 
are outlined.
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Introduction
Prostate cancer is second most common cancer in 
men, with an estimated 1,100,000 new cases and 
307,000 deaths in 2012 worldwide (1). Patients with 
localized prostate cancer are successfully treated by 
surgery and radiotherapy. For patients with metasta- 
tic prostate cancer, androgen deprivation therapy is 
the standard treatment. however, most of these pa-
tients progress into metastatic castration resistant 
prostate cancer (mCrPC) and eventually die after 
progression (2).
Different therapeutic approaches are studied for 
patients with mCrPC with special interest in immu-
notherapy. Cancer immunotherapy is any of various 
therapeutic approaches (cancer vaccines, immune 
checkpoint inhibitors (iCi), chimeric antigen receptor 
(CAr) t-cells, etc.) that aim at patient’s own immune 
system to make it more efficient at killing cancer cells. 
only approved therapeutic cancer vaccine, sipuleucel-
t, was approved for patients with asymptomatic or 
minimally symptomatic mCrPC (3). iCi are type of 
immunotherapy drugs that are currently widely used 
in different types of cancer (melanoma, lung cancer, 
bladder cancer, etc.) with significant therapeutic effect. 
however, clinical studies in prostate cancer have not 
shown significant therapeutic effect of iCi (4,5). to 
understand why iCi have failed so far as drugs for 
prostate cancer and to develop more efficient immu-
notherapies we need to better understand complex re-
lations between prostate cancer and immune system. 
recent discoveries in that field will be discussed later 
in this review.
understanding how immune system influences 
prostate cancer and vice versa could help us improve 
management of prostate cancer patients in many dif-
ferent ways. For example, it was shown that immune 
cells can be responsible for one mechanism of develop-
ing prostate cancer castration resistance (6). Studies 
also indicate that immunological mechanisms may be 
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responsible for beneficial effects of exercise that was 
shown to improve quality of life in patients with pros-
tate cancer (7).
Sipuleucel-T and other cancer vaccines
Sipuleucel-t was the first cancer vaccine that was 
approved for routine treatment of cancer patients. Af-
ter promising phase i/ii trial results, sipuleucel-t was 
analyzed in three large phase iii trials (8-10). First 
two of these trials had progression-free survival as pri-
mary endpoint that was not reached but both studies 
have shown better overall survival for patients treated 
with sipuleucel-t compared to placebo control (8,9). 
Pooled data from these two trials have shown median 
overall survival of 23.2 months in sipuleucel-t group 
versus 18.9 months in placebo control group (hazard 
ratio=0.67 (95% Ci 0.49-0.91), p=0.011) (8,9). in a 
pivotal phase iii study (imPACt trial) on 512 pa-
tients with mCrPC primary goal of prolonged overall 
survival was met (median 25.8 versus 21.7 months, 
hazard ratio=0.78 (95% Ci 0.61-0.98), p=0.03) (10). 
in all three clinical trials sipuleucel-t was well toler-
ated with most side effects being grade i or ii and re-
solving within two days (11). Based on results of im-
PACt trial, sipuleucel-t was approved in 2010 by the 
u.S. Food and Drug Administration for treatment of 
patients with asymptomatic or minimally symptom-
atic metastatic castrate resistant prostate cancer. Sipu-
leucel-t is also studied in other categories of prostate 
cancer patients. There is ongoing ProVent phase iii 
study testing effectiveness of sipuleucel-t in decreas-
ing histologic progression in patients with low-grade 
prostate cancer. Sipuleucel-t is not widely accepted 
with recent analysis showing that only 10% of eligible 
mCrPC patients in the uSA were treated with sipu-
leucel-t (12). reasons for low acceptance of sipuleu-
cel-t could be its high price and complexity of its ap-
plication compared to other drugs for mCrPC like 
abiraterone acetate and enzalutamide.
Sipuleucel-t is an individualized cancer vaccine 
prepared from patient’s peripheral blood mononuclear 
cells. These cells are harvested from patient’s blood and 
incubated ex vivo with recombinant antigen PA2024 
that consists of prostate cancer antigen prostatic acid 
phosphatase (PAP) fused to human granulocyte-mac-
rophage colony-stimulating factor (gm-CSF). gm-
CSF facilitates activation and maturation of dendritic 
cells that are returned to the patient. These dendritic 
cells are supposed to activate patient’s adaptive im-
mune response that will target prostate cancer cells 
that express PAP. immunological effects and mecha-
nisms of sipuleucel-t were studied to better under-
stand its complex activity but also to potentially find 
predictive biomarkers that would help select patients 
most likely to benefit from sipuleucel-t treatment. it 
was shown that sipuleucel-t induces infiltration of ac-
tivate t cells into prostate cancer tissue (13). Sipuleu-
cel-t also induces systemic t-cell response specific to 
PA2024 antigen that is related to its therapeutic effect 
on patients’ survival (14). in addition to cellular im-
munity, sipuleucel-t was shown to elicit adaptive hu-
moral immune response with igg antibodies specific 
to PAP and PA2014 antigens, but also to other non-
target prostate cancer antigens like PSA (15,16). Anti-
body response to non-target antigens PSA and 
lgAlS3 was associated with improved survival in 
prostate cancer patients treated with sipuleucel-t (16). 
Such antibody response to non-target antigens can be 
explained by antigen spread mechanism that could be 
responsible for part of therapeutic effect of sipuleucel-
t and other similar immunotherapies (17).
There are other cancer vaccines that have been 
studied in patients with prostate cancer but so far 
without results of clinical trials that would justify their 
use in routine practice (18). Cancer vaccine ProSt-
VAC-V/F based on recombinant vaccinia and fowlpox 
viral vectors genetically engineered to express prostate 
specific antigen (PSA) has shown very promising re-
sults in phase ii studies (19). however, large phase iii 
clinical study on 1297 patients failed to show Prost-
vac-V/F effect on patients’ survival (20).
Immune checkpoint inhibitors
immune checkpoint inhibitors (iCi) are antibodies 
that target inhibitory receptors on cytotoxic t cells 
(CtlA-4 and PD-1) or ligands for these receptors on 
other cells (PD-l1). in that way they block activation 
of these inhibitory receptors and in effect augment ac-
tivation of t cells with expected enhanced anti-cancer 
immune response. With proven significant therapeutic 
efficiency in different types of cancer these drugs have 
changed the landscape of cancer therapy in the last 
 decade.
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unfortunately, unlike in many other cancer types 
including renal cell carcinoma and urothelial carcino-
ma, iCi have shown very limited effect in prostate 
cancer. ipilimumab, anti-CtlA-4 antibody failed to 
show any improvement in overall survival in two phase 
iii studies on patients with mCrPC (21,22). The larg-
est study of anti-PD-1 antibody pembrolizumab in 
patients with mCrPC with published preliminary 
data, Keynote-199 showed objective response rate 
of 5% in 133 patients with measurable PD-l1-posi-
tive disease and 3% in 66 patients with measurable 
PD-l1-negative disease (23).
Immunological background of prostate cancer 
immunotherapy resistance and ways to  
overcome it
Current understanding of local and systemic rela-
tions between immune system and cancer in the con-
text of immunotherapy offers several explanations for 
failure of iCi in prostate cancer and potential strate-
gies to improve immunotherapy effects in patients 
with prostate cancer and select subgroups of patients 
that might respond to iCi.
Partial explanation for lack of response to iCi in 
prostate cancer can be low tumor mutation burden 
(number of mutations in cancer cells) in prostate can-
cer compared to some other types of cancer that have 
good response to iCi (e.g. melanoma and lung cancer) 
(24). higher tumor mutation burden was associated 
with better response to iCi in different types of cancer 
including prostate cancer (25,26). higher tumor mu-
tation burden relates to higher number of neoantigens 
expressed by cancer cells that can be recognized by cy-
totoxic t cells, principal type of cells activated by iCi. 
Cancers with deficient mismatch repair (dmmr), 
characterized with high level of microsatellite instabil-
ity (mSi-h) usually have more mutations compared 
to same types of cancer that are not deficient in mmr. 
Based on a study in different types of dmmr/mSi-h 
cancers that has shown high objective response rate 
with iCi, pembrolizumab was approved in 2017 by 
FDA for second-line treatment of dmmr/mSi-h 
advanced cancers of any histologic type (27). Preva-
lence of dmmr/mSi-h in prostate cancer is 3-8%, 
and these patients might be good candidates for iCi 
(28,29). retrospective analysis of eleven mCrPC pa-
tients with dmmr/mSi-h cancer treated with iCi 
has shown >50% decline in PSA levels in six patients 
and radiographic response in four patients (28). ge-
netic aberrations in prostate cancer in other genes re-
lated to DnA damage response (eg. BRCA2) might be 
associated with favorable response to iCi (30). it was 
shown that prostate cancer with loss of CDK12 gene 
found in 7% of mCrPC represents a distinct subgroup 
of prostate cancer with increased neoantigen load and 
potential response to iCi (31).
Another potential mechanism of escaping immune 
response by prostate cancer is downregulation of 
mhCi expression resulting with impaired antigen 
presentation to cytotoxic t cells. Potential marker of 
response to anti-PD1/PD-l1 iCi is expression of 
PD-l1 on cancer cells. however, response to iCi in 
prostate cancer does not appear to be related to PD-
l1 expression (23,30).
it was shown that analysis of tumor-infiltrating 
lymphocytes, but also more complex analysis of tumor 
immune microenvironment might predict cancer 
prognosis, response to immunotherapy and response 
to other modalities of cancer treatment (32,33). Based 
on presence and location of tumor-infiltrating lym-
phocytes, tumors are classified as immunologically 
“hot” (t cell inflamed) or “cold” (non-t cell inflamed). 
immunologically “hot” tumors are more likely to re-
spond to immunotherapy. Although t cell infiltrates 
can be found in prostate cancer, it is possible that these 
t cells are dysfunctional contributing to immunosup-
pressive prostate cancer immune microenvironment 
(33). immunosuppressive prostate cancer microenvi-
ronment might also be enhanced by the presence of 
immunosuppressive immune cells like regulatory t 
cells and myeloid-derived suppressive cells (mDSC) 
that were confirmed in prostate cancer tissues (34-36).
one strategy to overcome resistance and improve 
immunotherapy outcomes in patients with prostate 
cancer is to combine different immunotherapies (dual 
iCi, iCi + cancer vaccines) or immunotherapies with 
other types of therapy (iCi + PArP inhibitors, iCi + 
chemotherapy, iCi + radiotherapy, iCi + androgen-
deprivation therapy). These combinations are currently 
studied in many ongoing clinical trials (37-39). ratio-
nale for these combinations is based on current under-
standing of immune mechanisms of different thera-
peutic approaches: potential of cancer vaccines to in-
duce immune infiltration to tumor microenvironment 
and enhance effects of iCi, known immunomodula-
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tory effects of chemotherapy and radiotherapy, etc. 
(38,40).
Conclusion
Despite being the first cancer with approved cancer 
vaccine therapy, results of immunotherapy in prostate 
cancer so far have been disappointing compared to 
some other types of cancer. Several new therapeutic 
strategies to overcome prostate cancer immunotherapy 
resistance and to select subgroups of patients that 
could benefit from immunotherapy emerged from new 
insights into biology of prostate cancer and are ex-
plored in ongoing clinical studies. however, real clini-
cally important breakthrough in prostate cancer im-
munotherapy might come from future innovative ap-
proaches that will be based on deeper understanding 
of complex interplay between prostate cancer and im-
munity, interplay that we are only starting to fully 
comprehend.
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Sažetak
iZAZoVi mAniPulirAnJA imunoloŠKim SuStAVom  
u SVrhu liJeČenJA rAKA ProStAte
I. Šamija i A. Fröbe
Prva vakcina za rak koja je odobrena za rutinsko liječenje bio je sipuleucel-t za liječenje bolesnika s metastatskim kastra-
cijski rezistentnim rakom prostate. međutim, drugi imunoterapijski lijekovi koji su bili istraživani u bolesnika s rakom pro-
state, posebno inhibitori imunološke kontrolne točke, nisu pokazali terapijski učinak. nekoliko je mogućih objašnjenja za 
nedostatak terapijskog odgovora na ove lijekove kod raka prostate. ta objašnjenja koja su vezana uz specifična genetička (npr. 
nisko mutacijsko opterećenje) i imunološka (npr. imunosupresivni tumorski imunološki mikrookoliš) obilježja raka prostate 
opisana su u ovom preglednom radu. također, prikazane su nove terapijske strategije s ciljem prevladavanja otpornosti raka 
prostate na imunoterapiju i za odabir podskupina bolesnika u kojih se može očekivati korist od imunoterapije.
Ključne riječi: rak prostate; imunoterapija; vakcine za rak; inhibitori imunološke kontrolne točke; izmicanje tumora imunološkom 
nadzoru
